Department of Psychology, Durham University, Durham, DH1 3LE, England, UK.
Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, England, UK.
Harm Reduct J. 2023 May 12;20(1):66. doi: 10.1186/s12954-023-00785-y.
Heroin-Assisted Treatment (HAT) is well evidenced internationally to improve health and social outcomes for people dependent on opioids who have not been helped by traditional treatment options. Despite this evidence base, England has been slow to implement HAT. The first service outside of a trial setting opened in 2019, providing twice-daily supervised injections of medical-grade heroin (diamorphine) to a select sample of high-risk heroin users in Middlesbrough. This paper explores their experiences, including the negotiation of the strict regularly controls required of a novel intervention in the UK context.
We conducted in-depth interviews with service providers and users of the Middlesbrough HAT service between September and November 2021. Data from each group were thematically analysed and reported separately. This paper details the experiences of the twelve heroin dependent men and women accessing HAT.
Participants' accounts of HAT treatment evidenced a tension between the regulatory constraints and uncertainty of treatment provision, and the positive outcomes experienced through supportive service provision and an injectable treatment option. Limited confidence was held in treatment efficacy, longevity of funding, and personal capacity for treatment success. This was counteracted by a strong motivation to cease engagement with the illicit drug market. While attendance requirements placed restrictions on daily activities, participants also experienced benefits from strong, supportive bonds built with the service providers through their continued engagement.
The Middlesbrough HAT programme provided benefits to a high-risk population of opioid dependent people who were unable or disinclined to participate in conventional opioid substitution treatments. The findings in this paper highlight the potential for service modifications to further enhance engagement. The closure of this programme in 2022 prohibits this opportunity for the Middlesbrough community, but holds potential to inform advocacy and innovation for future HAT interventions in England.
海洛因成瘾治疗(HAT)在国际上得到了充分的证明,可以改善未通过传统治疗选择而受益的阿片类药物依赖者的健康和社会结果。尽管有这样的证据基础,但英国实施 HAT 的速度很慢。第一个在试验环境之外开设的服务于 2019 年在米德尔斯堡为一小部分高危海洛因使用者提供了每天两次的监督注射医用级海洛因(二乙酰吗啡),这是一项新颖的干预措施,在英国背景下需要严格定期控制。
我们在 2021 年 9 月至 11 月期间对米德尔斯堡 HAT 服务的服务提供者和使用者进行了深入访谈。对来自每个群体的数据进行了主题分析,并分别进行了报告。本文详细介绍了 12 名接受 HAT 治疗的男性和女性的经历,他们依赖海洛因。
参与者对 HAT 治疗的描述表明,在治疗提供的监管限制和不确定性与通过支持性服务提供和注射治疗选择获得的积极结果之间存在紧张关系。对治疗效果、资金的持久性和个人治疗成功的能力的信心有限。这与强烈的动机相抵消,即停止参与非法毒品市场。虽然出勤要求限制了日常活动,但参与者也通过与服务提供者持续参与建立的强大、支持性的联系获得了好处。
米德尔斯堡 HAT 计划为无法或不愿意参与常规阿片类药物替代治疗的高危阿片类药物依赖人群提供了好处。本文的研究结果强调了进一步增强参与度的服务修改的潜力。该计划于 2022 年关闭,禁止了米德尔斯堡社区的这一机会,但为未来在英格兰进行 HAT 干预提供了倡导和创新的潜力。